#USA #Tallahassee #PurMinds Enterprises #PFSF #Neurological Health

Major Transition for Pacific Software Inc.

On January 19, 2026, Pacific Software, Inc. (OTC: PFSF), known as PurMinds Enterprises, formally announced the successful conclusion of its significant corporate restructuring. Following the reverse takeover (RTO) with PurMinds Holdings Inc. on November 3, 2025, the company is setting foot in the expansive neurological health market valued over $1 trillion.

Acquisition and Rebranding

The journey began with a Stock Purchase Agreement signed on August 19, 2025, culminating in the acquisition of PurMinds Holdings, which owns all shares of 10763942 CANADA INC. Known as a pioneer in clinical-stage neuromedicine, PurMinds utilizes a unique "4P Medicine" platform that emphasizes Predictive, Preventive, Personalized, and Participatory treatment approaches. This model aims for early detection and proactive interventions in psychiatric and neurological conditions, significantly improving patient outcomes.

Official Name Change

Along with the acquisition, the company received approval for its new corporate name and is in the process of updating its trading ticker symbol with FINRA. This step aligns with its refreshed mission and vision focusing on impactful healthcare solutions.

Final Capital Structure

In light of the RTO completed, the company is refining its capital structure to reflect a 90/10 equity distribution as laid out in the Share Purchase Agreement. This crucial action is part of a broader strategy to ensure a seamless transition while clearing any legacy administrative hurdles relating to share registrations.

New Facility for Research and Production

On January 12, 2026, PurMinds confirmed its full occupancy of a state-of-the-art pharmaceutical manufacturing and research facility, spanning 20,477 square feet. This site adheres to stringent cGMP standards, an essential move to bolster its regulatory framework. The facility had previously held licenses for controlled substances and drug establishment, which the new management intends to leverage as they pursue necessary certifications from Health Canada and the U.S. FDA.

Uplisting Strategy

In furthering its expansion goals and bolstering investor confidence, the company has initiated collaboration with a PCAOB-registered audit firm. This strategic move is a stepping stone towards uplisting from the OTC Pink market to the prestigious OTCQX® Best Market. It is anticipated that this transition will occur in the first half of 2026.

Financial Reporting Insights

The company has released its Annual Report on Form 10-K. It's essential to note that this document reflects the company’s financials prior to the RTO, providing a snapshot before the merger. Subsequently, the upcoming Quarterly Report for the period ending December 31, 2025, scheduled for release on February 14, 2026, will be the first to depict the consolidated financial picture of PurMinds Enterprises.

Management’s Vision

"The occupancy of our GMP facility represents a crucial physical milestone in our transition," stated Angelo Pizzuto, the Treasury and COO of PurMinds Enterprises. “This facility is designed to meet all licensing requirements, enhancing our position in the neuromedicine sector. As we clear legacy debts and secure specialized talent, we envision a robust future spearheaded by our upcoming 10-Q report, which will highlight the newfound potential for PurMinds Enterprises, Inc."

About PurMinds Enterprises

PurMinds™ is dedicated to advancing neuro-medicine, focused on pioneering solutions for neurological and psychiatric disorders. The company’s clinical pipeline includes innovative neuroprotective compounds aimed at restoring neuronal functions and addressing significant unmet patient needs. Their partnership with SpectroChip Global Inc. aligns with the 4P Medicine philosophy to facilitate timely interventions before conditions escalate.

Conclusion

As Pacific Software transitions into PurMinds Enterprises, it sets a foundation for transformative changes within the neurological health sector, promising groundbreaking developments in neuro-medicine that could alter the treatment landscape significantly.